Teva Pharmaceutical (TEVA) is currently trading at new 5-year highs, with shares up over 40% in the past year. The stock has strong technical momentum and maintains a 100% “Buy” opinion from Barchart. TEVA offers international diversification and is favored by both Wall Street and individual investors. The company has a market capitalization of $36.40 billion and offers a range of generic and branded drugs, including products like Copaxone and ProAir. Analysts and investors are bullish on TEVA, with price targets ranging from $20 to $48. Overall, TEVA is seen as a solid choice for international exposure in the pharmaceutical sector.

Read more at Barchart: This International Pharma Stock Just Hit 5-Year Highs